The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Mammalian Target of Rapamycin Inhibitor Everolimus in Patients With Advanced Solid Tumors
Abstract
Purpose: To identify the optimal regimen and dosage of the oral mammalian target of rapamycin inhibitor everolimus (RAD001). Methods: We performed a dose-escalation study in advanced cancer patients administering oral everolimus 5 to 30 mg/wk, with pharmacokinetic (PK) and pharmacodynamic (PD) studies. PD data prompted investigation of 50 and 70 mg weekly and daily dosing at 5 and 10 mg. Results: Ninety-two patients were treated. Dose-limiting toxicity was seen in one patient each at 50 mg/wk (stomatitis and fatigue) and 10 mg/d (hyperglycemia); hence, the maximum-tolerated dose was not reached. S6 kinase 1 activity in peripheral-blood mononuclear cells was inhibited for at least 7 days at doses ≥ 20 mg/wk. Area under the curve increased proportional to dose, but maximum serum concentration increased less than proportionally at doses ≥ 20 mg/wk. Terminal half-life was 30 hours (range, 26 to 38 hours). Partial responses were observed in four patients, and 12 patients remained progression free for ≥ 6 months, including five of 10 patients with renal cell carcinoma. Conclusion: Everolimus was satisfactorily tolerated at dosages up to 70 mg/wk and 10 mg/d with predictable PK. Antitumor activity and PD in tumors require further clinical investigation. Doses of 20 mg/wk and 5 mg/d are recommended as appropriate starting doses for these studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma
Hudes, G., Carducci, M., Tomczak, P., Dutcher, J., Figlin, R., Kapoor, A., Staroslawska, E., Sosman, J., McDermott, D., Bodrogi, I., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa066838 · Cited by 3,647
mTOR Inhibition Induces Upstream Receptor Tyrosine Kinase Signaling and Activates Akt
O'Reilly, K. E., Rojo, F., She, Q.-B., Solit, D., Mills, G. B., Smith, D., Lane, H., Hofmann, F., Hicklin, D. J., Ludwig, D. L., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2925 · Cited by 2,561
Self-citationEisen, H. J., Tuzcu, E. M., Dorent, R., Kobashigawa, J., Mancini, D., Valantine-von Kaeppler, H. A., Starling, R. C., Sørensen, K., Hummel, M., Lind, J. M., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022171 · Cited by 1,198
Current development of mTOR inhibitors as anticancer agents
Faivre, S., Kroemer, G., & Raymond, E. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2062 · Cited by 1,000
Self-citationmTOR, translation initiation and cancer
Mamane, Y., Petroulakis, E., LeBacquer, O., & Sonenberg, N. (2006) · Oncogene · doi:10.1038/sj.onc.1209888 · Cited by 607 · cited 1×
“The mTOR kinase also controls angiogenic pathways via hypoxia-inducible factor-1 and vascular endothelial growth factor and via endothelial and smooth muscle cell proliferation.(1,2) mTOR substrates, activating signaling pathways, and mTOR itself have been shown to be dysregulated in a variety of human malignancies, m…”
BackgroundRaymond, E., Alexandre, J., Faivre, S., Vera, K., Materman, E., Boni, J., Leister, C., Korth-Bradley, J., Hanauske, A., & Armand, J.-P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.116 · Cited by 499
Self-citationBeuvink, I., Boulay, A., Fumagalli, S., Zilbermann, F., Ruetz, S., O’Reilly, T., Natt, F., Hall, J., Lane, H. A., & Thomas, G. (2005) · Cell · doi:10.1016/j.cell.2004.12.040 · Cited by 486
Self-citationEaston, J. B., & Houghton, P. J. (2006) · Oncogene · doi:10.1038/sj.onc.1209886 · Cited by 459
Upstream of the mammalian target of rapamycin: do all roads pass through mTOR?
Corradetti, M. N., & Guan, K.-L. (2006) · Oncogene · doi:10.1038/sj.onc.1209885 · Cited by 386
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Self-citationBoulay, A., Zumstein-Mecker, S., Stephan, C., Beuvink, I., Zilbermann, F., Haller, R., Tobler, S., Heusser, C., O’Reilly, T., Stolz, B., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-3554-2 · Cited by 318
Self-citationSIROLIMUS-ASSOCIATED PULMONARY TOXICITY
Pham, P.-T. T., Pham, P.-C. T., Danovitch, G. M., Ross, D. J., Gritsch, H. A., Kendrick, E. A., Singer, J., Shah, T., & Wilkinson, A. H. (2004) · Transplantation · doi:10.1097/01.tp.0000118413.92211.b6 · Cited by 298
Goudar, R. K., Shi, Q., Hjelmeland, M. D., Keir, S. T., McLendon, R. E., Wikstrand, C. J., Reese, E. D., Conrad, C. A., Traxler, P., Lane, H. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.101.4.1 · Cited by 243
Self-citationBrief Communication: Sirolimus-Associated Pneumonitis: 24 Cases in Renal Transplant Recipients
Champion, L., Stern, M., Israël-Biet, D., Mamzer-Bruneel, M.-F., Peraldi, M.-N., Kreis, H., Porcher, R., & Morelon, E. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-144-7-200604040-00009 · Cited by 184
Kovařík, J. (2001) · Clinical Pharmacology & Therapeutics · doi:10.1067/mcp.2001.112969 · Cited by 153
Characterisation of the lung toxicity of the cell cycle inhibitor temsirolimus
Durán, I., Siu, L. L., Oza, A. M., Chung, T., Sturgeon, J. F. G., Townsley, C. A., Pond, G. R., Seymour, L., & Niroumand, M. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.015 · Cited by 152
Review of the proliferation inhibitor everolimus
Nashan, B. (2002) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.11.12.1845 · Cited by 124
Brignol, N., McMahon, L. M., Luo, S., & Tse, F. L. S. (2001) · Rapid Communications in Mass Spectrometry · doi:10.1002/rcm.323 · Cited by 84
Kovarik, J. M., Hartmann, S., Figueiredo, J., Rordorf, C. M., Golor, G., Lison, A. E., Budde, K., & Neumayer, H. H. (2002) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.22.3.154.33542 · Cited by 84
Self-citationKovarik, J. M., Eisen, H. J., Dorent, R., MANCINI, D. M., Viganò, M., Rouilly, M., Hsu, C.-H., & Rordorf, C. M. (2003) · The Journal of Heart and Lung Transplantation · doi:10.1016/s1053-2498(02)01221-4 · Cited by 67
Self-citationPascual, J., Boletis, I. N., & Campistol, J. M. (2006) · Transplantation Reviews · doi:10.1016/j.trre.2005.10.005 · Cited by 62
Budde, K., Neumayer, H. H., Lehne, G., et al. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh322 · Cited by 46
Desai, A. A., Janisch, L. A., Berk, L. R., Knowles, H., Rivera, V. M., Bedrosian, C. L., & Ratain, M. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.22.90140.3150 · Cited by 32
Liberopoulos, E. N., Miltiadous, G. A., Cariolou, M. A., Kalaitzidis, R., Siamopoulos, K. C., & Elisaf, M. (2004) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfh349 · Cited by 25
The PI3-K/AKT/mTOR pathway as a target for breast cancer therapy
Cosimo, S. D., Scaltriti, M., del Val, D. J., Rojo, F., Guzmán, M., Jimenez, J., Seoane, J., Arribas, J., & Baselga, J. M. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.25.18_suppl.3511 · Cited by 22
Cited by
Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing
Gerlinger, M., Rowan, A. J., Horswell, S., Larkin, J., Endesfelder, D., Gronroos, E., Martinez, P., Matthews, N., Stewart, A., Tarpey, P., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1113205 · Cited by 7,774
Motzer, R. J., Escudier, B., Oudard, S., Hutson, T. E., Porta, C., Bracarda, S., Grünwald, V., Thompson, J. A., Figlin, R. A., Hollaender, N., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61039-9 · Cited by 3,019
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
Yao, J. C., Shah, M. H., Ito, T., Bohas, C. L., Wolin, E. M., Van Cutsem, E., Hobday, T. J., Okusaka, T., Capdevila, J., de Vries, E. G. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009290 · Cited by 2,876
Targeting PI3K/Akt/mTOR Signaling in Cancer
Porta, C., Paglino, C., & Mosca, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00064 · Cited by 1,485
Targeting PI3K/mTOR Signaling in Cancer
Arcaro, A. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00084 · Cited by 1,024
Metadata
- Authors
- O'Donnell, A., Faivre, S., Burris, H. A., Rea, D., Papadimitrakopoulou, V., Shand, N., Lane, H. A., Hazell, K., Zoellner, U., Kovarik, J. M., Brock, C., Jones, S., Raymond, E., & Judson, I.
- Venue
- Journal of Clinical Oncology
- Published
- 2008-04-01
- Volume
- 26
- Issue
- 10
- Pages
- 1588-1595
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2153493705
- Cited by
- 479
- References
- 26
- FWCI
- 19.11
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.